It's Time For a Quick Look at Regeneron Pharmaceuticals (REGN)'s Fundamentals

After moving 0.7% during today's evening session, Regeneron Pharmaceuticals is now trading at a price of $830.69 per share. On average, analysts give it a target price of $898.86.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

Potential Regeneron Pharmaceuticals Investors Should Analyze the Following:

  • Regeneron Pharmaceuticals has moved 15.0% over the last year.

  • The company has a price to earnings growth (PEG) ratio of 4.2. A number between 0 and 1 could mean that the market is undervaluing Regeneron Pharmaceuticals's estimated growth potential

  • Its Price to Book (P/B) ratio is 3.68

Understanding Regeneron Pharmaceuticals's Operating Margins

Date Reported Total Revenue ($ k) Operating Expenses ($ k) Operating Margins (%) YoY Growth (%)
2023-02-06 12,172,900 -5,618,500 41 -26.79
2022-02-07 16,071,700 -4,639,400 56 30.23
2021-02-08 8,497,100 -3,712,600 43 26.47
2020-02-07 6,557,600 -3,582,700 34 -30.61
2019-02-07 5,145,600 -2,193,700 49 40.0
2018-02-08 5,872,200 -3,395,500 35

Regeneron Pharmaceuticals's operating margins have averaged 43.0% over the last 6 years, which is significantly higher than the Pharmaceutical industry average of 12.02%. The firm's margins exhibit a relatively stable growth trend of 2.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.